Company Filing History:
Years Active: 2021-2024
Title: Innovations by Jacques Ravel
Introduction
Jacques Ravel is an accomplished inventor based in Laurel, MD (US). He has made significant contributions to the field of microbiome research, particularly in relation to preterm infants and biotherapeutics. With a total of 5 patents, Ravel's work is at the forefront of medical innovation.
Latest Patents
Ravel's latest patents include groundbreaking research on predicting necrotizing enterocolitis in preterm infants. This patent discloses a correlative finding between increased Clostridiales and/or Bifidobacteriales bacterial abundance in the gut and the maturation of the intestinal barrier in at-risk preterm neonates. These findings form the basis for methods to identify preterm infants at risk for developing necrotizing enterocolitis (NEC) and provide treatment strategies for such infants. Another notable patent involves a microbiome-based informed method to formulate live biotherapeutics. This method identifies deficiencies or excesses of specific bacterial strains in a person's microbiome and formulates biotherapeutics to address these imbalances. This innovation may improve the health of a person's vaginal microbiome and could be suitable for treating malignancies in the female genitourinary system.
Career Highlights
Ravel is affiliated with the University System of Maryland, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on neonatal health and microbiome therapies.
Collaborations
Some of Ravel's notable coworkers include Bing Ma and Michael France, who contribute to the collaborative efforts in his research endeavors.
Conclusion
Jacques Ravel's innovative work in microbiome research and biotherapeutics highlights the importance of understanding bacterial interactions in health and disease. His contributions are paving the way for new treatment methods that could significantly benefit vulnerable populations, particularly preterm infants.